Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
:AVBP
AVBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.35 - $36.37
Previous CloseN/A
Volume49.09K
Average Volume (3M)172.27K
Market Cap
$742.35M
Enterprise Value$509.18M
Total Cash (Recent Filing)$163.37M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 07, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding33,697,163
10 Day Avg. Volume214,694
30 Day Avg. Volume172,270
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.21
Forecast
1Y Price Target
$38.50Price Target Upside74.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ArriVent BioPharma, Inc. News
PremiumCompany Announcements
ArriVent BioPharma Reports 2024 Financial Results and ProgressPremiumCompany Announcements
ArriVent BioPharma Expands Oncology Pipeline with New License---
Bulls Say, Bears Say
Bulls Say
Market OpportunityThere is currently no FDA-approved agent for non-small cell lung cancer patients with EGFR PACC mutations, highlighting the potential market opportunity for firmonertinib.
Regulatory AdvantageFirmonertinib was granted Breakthrough Therapy Designation by the FDA for patients with advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Bears Say
Financial ChallengesThe company has less than two years of cash runway remaining, which may pose financial challenges.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $14.35 and its highest was $36.37 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $742.35M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 07, 2025 which is in 63 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 03, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.665 by $0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.68.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 33,697,163 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.665. Following the earnings report the stock price went down -6.692%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
---
ArriVent BioPharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.50 (74.76% Upside)
$38.50 (74.76% Upside)
Hedge Fund Trend
Decreased
By 390.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.20%
12-Months-Change
Fundamentals
Return on Equity
-39.36%
Trailing 12-Months
Asset Growth
68.57%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
---
AVBP Stock 12 Month Forecast
Average Price Target
$38.50
▲(74.76% Upside)
Technical Analysis
Fate Therapeutics
―
Sorrento Therapeutics
―
Aldeyra Therapeutics
―
Atara Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering AVBP
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
+1.54%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +1.54% per trade.
---